Our Shield™ blood test gains FDA approval, ushering in a new era of colorectal cancer screening.  More details

04/11/2022

Development of a Highly-Sensitive Targeted Cell-Free DNA Epigenomic Assay for Early-Stage Multi-Cancer Screening

A blood-based cancer screening test should exhibit performance metrics optimized for the cancer of interest…

Back to Blog Listing

Sign up to receive the latest updates on ShieldTM

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.